These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

212 related articles for article (PubMed ID: 29065822)

  • 21. Antiprotozoal Activity Profiling of Approved Drugs: A Starting Point toward Drug Repositioning.
    Kaiser M; Mäser P; Tadoori LP; Ioset JR; Brun R
    PLoS One; 2015; 10(8):e0135556. PubMed ID: 26270335
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The Role of Natural Products in Drug Discovery and Development against Neglected Tropical Diseases.
    Cheuka PM; Mayoka G; Mutai P; Chibale K
    Molecules; 2016 Dec; 22(1):. PubMed ID: 28042865
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The kinetoplastid chemotherapy revisited: current drugs, recent advances and future perspectives.
    Castillo E; Dea-Ayuela MA; Bolás-Fernández F; Rangel M; González-Rosende ME
    Curr Med Chem; 2010; 17(33):4027-51. PubMed ID: 20939823
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Antiprotozoal agents: How have they changed over a decade?
    Fernandes VS; da Rosa R; Zimmermann LA; Rogério KR; Kümmerle AE; Bernardes LSC; Graebin CS
    Arch Pharm (Weinheim); 2022 Feb; 355(2):e2100338. PubMed ID: 34661935
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Complementary medicinal chemistry-driven strategies toward new antitrypanosomal and antileishmanial lead drug candidates.
    Cavalli A; Lizzi F; Bongarzone S; Belluti F; Piazzi L; Bolognesi ML
    FEMS Immunol Med Microbiol; 2010 Feb; 58(1):51-60. PubMed ID: 19845762
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Development of novel drugs for human African trypanosomiasis.
    Brun R; Don R; Jacobs RT; Wang MZ; Barrett MP
    Future Microbiol; 2011 Jun; 6(6):677-91. PubMed ID: 21707314
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Retrospective Review of Chromane Analogues as Anti-protozoal Leads: A Decade's Worth of Evolution.
    Jadhav SR; Karan Kumar B; Joshi RP; Suryakant CK; Chandu A; Muzaffar-Ur-Rehman M; Khetmalis YM; Nandikolla A; Murugesan S; Chandra Sekhar KVG
    Curr Top Med Chem; 2023; 23(9):713-735. PubMed ID: 36786146
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Privileged small molecules against neglected tropical diseases: A perspective from structure activity relationships.
    Abbasi Shiran J; Kaboudin B; Panahi N; Razzaghi-Asl N
    Eur J Med Chem; 2024 May; 271():116396. PubMed ID: 38643671
    [TBL] [Abstract][Full Text] [Related]  

  • 29. In Silico Chemogenomics Drug Repositioning Strategies for Neglected Tropical Diseases.
    Andrade CH; Neves BJ; Melo-Filho CC; Rodrigues J; Silva DC; Braga RC; Cravo PVL
    Curr Med Chem; 2019; 26(23):4355-4379. PubMed ID: 29521204
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Flavonoids as efficient scaffolds: Recent trends for malaria, leishmaniasis, Chagas disease, and dengue.
    Boniface PK; Ferreira EI
    Phytother Res; 2019 Oct; 33(10):2473-2517. PubMed ID: 31441148
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Antiprotozoal Activities of Tetrazole-quinolines with Aminopiperidine Linker.
    Hochegger P; Faist J; Seebacher W; Saf R; Mäser P; Kaiser M; Weis R
    Med Chem; 2019; 15(4):409-416. PubMed ID: 30324885
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Small molecules containing chalcogen elements (S, Se, Te) as new warhead to fight neglected tropical diseases.
    Henriquez-Figuereo A; Morán-Serradilla C; Angulo-Elizari E; Sanmartín C; Plano D
    Eur J Med Chem; 2023 Jan; 246():115002. PubMed ID: 36493616
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Innovative lead compounds and formulation strategies as newer kinetoplastid therapies.
    Espuelas S; Plano D; Nguewa P; Font M; Palop JA; Irache JM; Sanmartín C
    Curr Med Chem; 2012; 19(25):4259-88. PubMed ID: 22834813
    [TBL] [Abstract][Full Text] [Related]  

  • 34. π-Delocalized Lipophilic Cations as New Candidates for Antimalarial, Antitrypanosomal and Antileishmanial Agents: Synthesis, Evaluation of Antiprotozoal Potency, and Insight into Their Action Mechanisms.
    Takasu K
    Chem Pharm Bull (Tokyo); 2016; 64(7):656-67. PubMed ID: 27373622
    [TBL] [Abstract][Full Text] [Related]  

  • 35. New bicyclic amines: synthesis and SARs of their action against the causative organisms of malaria and sleeping sickness.
    Weis R; Seebacher W
    Curr Med Chem; 2009; 16(11):1426-41. PubMed ID: 19355897
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Systematic review of antiprotozoal potential of antimicrobial peptides.
    Santos FA; Cruz GS; Vieira FA; Queiroz BRS; Freitas CDT; Mesquita FP; Souza PFN
    Acta Trop; 2022 Dec; 236():106675. PubMed ID: 36057367
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Challenges in drug discovery targeting TriTryp diseases with an emphasis on leishmaniasis.
    Alcântara LM; Ferreira TCS; Gadelha FR; Miguel DC
    Int J Parasitol Drugs Drug Resist; 2018 Dec; 8(3):430-439. PubMed ID: 30293058
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Potent antiprotozoal activity of a novel semi-synthetic berberine derivative.
    Bahar M; Deng Y; Zhu X; He S; Pandharkar T; Drew ME; Navarro-Vázquez A; Anklin C; Gil RR; Doskotch RW; Werbovetz KA; Kinghorn AD
    Bioorg Med Chem Lett; 2011 May; 21(9):2606-10. PubMed ID: 21474310
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Drug discovery and development for neglected diseases: the DNDi model.
    Chatelain E; Ioset JR
    Drug Des Devel Ther; 2011 Mar; 5():175-81. PubMed ID: 21552487
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Nanopharmaceuticals as a solution to neglected diseases: Is it possible?
    Islan GA; Durán M; Cacicedo ML; Nakazato G; Kobayashi RKT; Martinez DST; Castro GR; Durán N
    Acta Trop; 2017 Jun; 170():16-42. PubMed ID: 28232069
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.